OFIX Stock Forecast: Orthofix Medical, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Orthofix Medical, Inc. hold a median 12-month price target of $10 — +64.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 60 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Orthofix Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Issuance (21): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OFIX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OFIX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +64.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $18 → $13 |
| 6 July 2026 | Barrington Research | Maintains | Outperform | $15 → $17 |
| 22 May 2026 | Barrington Research | Maintains | Outperform | — |
| 22 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 22 May 2026 | Stifel | Maintains | Buy | — |
| 10 Apr 2026 | Barrington Research | Maintains | Outperform | — |
| 9 Mar 2026 | Stifel | Maintains | Buy | — |
| 26 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 17 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 27 Jan 2026 | TD Cowen | Initiates | Hold | — |
| 5 Nov 2025 | Barrington Research | Maintains | Outperform | — |
| 28 Oct 2025 | Stifel | Reinstates | Buy | $22 |
| 23 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 23 June 2025 | Barrington Research | Initiates | Outperform | — |
| 6 June 2025 | JMP Securities | Reiterates | Market Perform | — |
| 26 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 26 Feb 2025 | Roth MKM | Reiterates | Buy | — |
| 22 Jan 2025 | Canaccord Genuity | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OFIX.
This page is one stock. Monday covers all of them.
OFIX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OFIX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Orthofix Medical, Inc. returned −57.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OFIX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.3×
- Price / book
- 0.6×
- EV / EBITDA
- 10.3×
Cheaper than 86% of US stocks
Cheaper than 84% of US stocks
Cheaper than 55% of US stocks
- Revenue growth (YoY)
- 1.1%
- Earnings growth (YoY)
- —
- Gross margin
- 71.0%
- Operating margin
- −2.1%
- Net margin
- −5.4%
Higher than 31% of US stocks
Higher than 83% of US stocks
Higher than 32% of US stocks
Higher than 24% of US stocks
- Return on equity
- −10.3%
- Return on assets
- −1.3%
- Dividend yield
- —
Higher than 36% of US stocks
Higher than 39% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Orthofix Medical, Inc. has a market value of $247.4M and an enterprise value of $423.2M.
Revenue in the twelve months to 30 June 2026: $833.2M. The latest quarter grew 3.8% year on year.
Net income over the same four quarters: −$61.7M, a −7.4% net margin.
Diluted earnings per share, trailing twelve months: −$1.54.
Free cash flow in the twelve months to 30 June 2026: −$27.8M, after $44.1M of capital spending.
forward P/E: 33.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Orthofix Medical, Inc. employs 1,605 people — $519K of revenue per employee.
Data provided by Twelve Data
OFIX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OFIX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Orthofix Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OFIX
What is the OFIX stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Orthofix Medical, Inc. have a median 12-month price target of $10, with estimates ranging from $9 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OFIX stock a buy right now?
Of the 4 analysts covering Orthofix Medical, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Orthofix Medical, Inc. 60 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OFIX?
As at 21 Nov 2026, Orthofix Medical, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
Will OFIX stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +64.7% from the last close, and Ticker Nerd's factor model ranks Orthofix Medical, Inc. 60 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OFIX stock forecast for 2030?
No analyst covering Orthofix Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OFIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $11 over the next 12 months.
How has OFIX stock performed over the past year?
Orthofix Medical, Inc. returned -57.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Orthofix Medical, Inc. do?
Orthofix Medical Inc. is a global medical technology company focused on spine and orthopedic care. The company develops and markets a broad portfolio of spinal implants, bone growth therapies, biologics, and enabling technologies used by surgeons and healthcare providers to treat complex musculoskeletal conditions.
About Orthofix Medical, Inc.
Orthofix Medical Inc. is a global medical technology company focused on spine and orthopedic care. The company develops and markets a broad portfolio of spinal implants, bone growth therapies, biologics, and enabling technologies used by surgeons and healthcare providers to treat complex musculoskeletal conditions. Its product range also includes limb reconstruction and deformity correction solutions, as well as image-guided navigation systems that support surgical planning and execution. Orthofix Medical serves hospitals, ambulatory surgery centers, and medical specialists across multiple care settings, with products designed to address trauma, degenerative disorders, fracture management, and other orthopedic applications. Headquartered in Lewisville, Texas, Orthofix Medical plays a specialized role in the medical devices market by providing technology-driven solutions for reconstructive and regenerative musculoskeletal treatment.
CEO Mr. Massimo Calafiore · 1,605 employees · United States · https://orthofix.com